|1.||Kyprianou, Natasha: 10 articles (11/2007 - 01/2002)|
|2.||Kyprianou, N: 5 articles (07/2001 - 01/2000)|
|3.||Michel, Martin C: 3 articles (09/2014 - 01/2006)|
|4.||Guh, Jih-Hwa: 3 articles (06/2011 - 02/2003)|
|5.||Lepor, Herbert: 3 articles (01/2011 - 07/2003)|
|6.||Ku, Ja Hyeon: 3 articles (03/2009 - 05/2006)|
|7.||Tahmatzopoulos, Anastasios: 3 articles (05/2005 - 04/2004)|
|8.||Jacobs, S C: 3 articles (07/2001 - 08/2000)|
|9.||Suzuki, Y: 3 articles (04/2001 - 01/2001)|
|10.||Mitropoulos, Dionisios: 2 articles (04/2013 - 01/2009)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
12/01/1988 - "The results at four months of a six-month study support the conclusion that terazosin is beneficial for treatment of symptoms in patients with benign prostatic hypertrophy."
10/01/1989 - "These preliminary results confirm that terazosin significantly improved peak as well as mean urine flow rates and significantly reduced residual volume and significantly improved obstructive symptoms in patients with benign prostatic hyperplasia (p less than 0.001). "
11/01/2007 - "The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE. "
01/01/1992 - "Terazosin was found to be safe and effective in the dose range of 2-20 mg taken at bedtime in men with symptoms related to benign prostatic hyperplasia. "
03/01/1996 - "This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH). "
|2.||Hypertension (High Blood Pressure)
05/01/1987 - "Terazosin therapy results in a significant reduction in blood pressure in patients with mild to moderate essential hypertension, with little influence on heart rate. "
05/23/1986 - "The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies. "
05/23/1986 - "This study demonstrates that terazosin is effective and safe for long-term treatment of hypertension."
05/23/1986 - "The results of these studies indicate that combination therapy with terazosin plus a diuretic is both safe and effective for the treatment of hypertension."
05/23/1986 - "On the basis of these studies, it appears that terazosin, when administered once daily as monotherapy, is both safe and effective for the treatment of mild to moderate hypertension."
|3.||Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
04/01/1996 - "Terazosin treatment results in symptomatic relief and improved urinary flow in patients with and without bladder outlet obstruction, and in significant improvement in patients with urodynamically proved obstruction."
01/01/2000 - "Terazosin in a dose of 10 mg/day was well tolerated and effective in reducing bladder outlet obstruction in many spinal cord-injured patients, as reflected by a decrease in maximum detrusor pressure and MUPG in 49% of the patients. "
06/01/2002 - "Terazosin treatment, even 2 mg. daily, urodynamically relieved bladder outlet obstruction in Japanese patients with symptomatic BPH without any changes in detrusor contractility."
10/01/2006 - "These results suggest that terazosin may be an effective treatment option in women with voiding dysfunction due to functional bladder outlet obstruction."
10/01/2006 - "In a prospective pilot study 15 women with functional bladder outlet obstruction were treated with terazosin. "
02/01/1996 - "Terazosin given once daily in a dose ranging from 2 to 10 mg in community-based urology practices under conditions simulating usual care is effective in reducing the symptoms, perception of bother, and the impairment of QQL due to urinary symptoms in men with moderate to severe symptoms of prostatism. "
03/01/1996 - "Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms."
07/01/1995 - "Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms."
07/01/1995 - "Our study demonstrates that terazosin is not effective for the treatment of prostatism-like symptoms in aging women."
03/01/1997 - "To determine if men with normal peak urinary flow rates (PFR) and prostatism respond to terazosin. "
|5.||Prostatic Neoplasms (Prostate Cancer)
05/22/2004 - "This study provided the evidence that alpha1-adrenoceptor antagonist terazosin may have a therapeutic potential in the treatment of advanced androgen-independent prostate cancer."
05/22/2004 - "This study showed that terazosin inhibited not only prostate cancer cell growth but also colony-forming ability, which is the main target of clinical treatment. "
11/01/2003 - "This study shows that terazosin inhibits not only prostate cancer cell growth but also its colony forming ability, both of which are main targets of clinical treatment. "
11/01/2003 - "To study the effects of an alpha(1)-adrenoceptor antagonist, terazosin on the androgen-independent prostate cancer cell lines PC-3 and DU145. "
09/01/2003 - "The aim of the present study was to investigate the mechanisms involved in terazosin-induced prostate cancer cell death using two androgen-independent cell lines, PC-3 and DU145. "
|4.||Antihypertensive Agents (Antihypertensives)
|3.||Transurethral Resection of Prostate (TURP)
|4.||Drug Therapy (Chemotherapy)